Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGG492 in Partial Onset Seizures
NCT01147003Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of selurampanel in focal onset seizure (3 arms), sponsored by Novartis. Primary endpoint: Percent change in seizure frequency of BGG492 from baseline to maintenance period at 28 days. Started Jun 2010; status: completed.
02
Drugs
selurampanel
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT01147003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147003.